PAVMED INC
PAVMNASDAQ🏆 #3508 by market capUS Equity
$402.02▲ $28.26 (+7.03%)
Simulated price1h—
24h▲ 7.0%
7d—
14d—
30d—
1y—
🏦Market Cap
$34M
Small Cap
📈Revenue Growth (YoY)
-95.7%
Declining
📊Gross Margin
-227.1%
Thin
💵FCF Margin
—
⚖️P/S Ratio
400.1x
Expensive
Otter Score
66
Fair
No chart data available for PAVM.
Trading Snapshot
- Day Range
- $398.42 – $409.90
- 52-Week Range
- $3.85 – $28.44
- Volume
- $4.41B
- Avg Volume
- $4.98B
- Shares Outstanding
- 7.2M
- Next Earnings
- Oct 25, 2026
Fundamentals Snapshot
- Annual Revenue
- $84,284
- Last Q Revenue
- $20,085
- P/E Ratio
- —
- P/S Ratio
- 400.1x
- EPS (TTM)
- $-28.72
- Dividend Yield
- —
Why Investors Own PAVM
- ✓High-growth profile — revenue up +25.5% YoY with expanding US Equity exposure.
- ✓Healthy economics — 78% gross margin and 28% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$84,284▲ +25.8% YoY
Gross Margin (TTM)
78.1%▲ +2.8% YoY
Operating Income (TTM)
$27,308▲ +25.8% YoY
Free Cash Flow (TTM)
$23,768▲ +25.8% YoY
About PAVMED INC
A company profile for PAVMED INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Fair
66/100
Analyst Price Target
ⓘAverage Target
$473.76
▲ +17.8% Upside
High Target$514.92
Low Target$374.69
Based on 14 analysts
Latest News & Updates
🚀
Bloomberg·2h ago
PAVMED INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Reuters·5h ago
Analysts lift PAVM price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
MarketWatch·1d ago
PAVMED INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.